Search Results

• • 246 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Lenalidomide induces ubiquitination and degradation of CK1[alpha] in del(5q) MDS

  Authors:Jan Kronke, Emma C. Fink, Paul W. Hollenbach, Kyle J. MacBeth, Slater N. Hurst, Namrata D. Udeshi, et al.From:Nature (Vol. 523, Issue 7559) Peer-Reviewed

  July 9, 20159,687 words Report 1530LLenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Here, we demonstrate that lenalidomide induces the ubiquitination of casein kinase 1A1...

• Cyclophosphamide: myelodysplastic syndrome and acute myelomonocytic leukaemia: case report

  From:Reactions Weekly (Issue 1234)

  Jan. 10, 2009278 words Brief article, Case ... [S] A 64-year-old man developed myelodysplastic syndrome (MDS) and acute myelomonocytic leukaemia during treatment with cyclophosphamide for Wegener's granulomatosis; he later died of sepsis. In March 2004, the...

• Howell-Jolly Body-Like Inclusions in Neutrophils of Patients With Myelodysplastic Syndrome: A Novel Correlation

  Authors:Yi Tat Tong, Nghia D. Nguyen, and Amer WahedFrom:Archives of Pathology & Laboratory Medicine (Vol. 143, Issue 1) Peer-Reviewed

  Jan. 20191,191 words Report 1390L* Context.--Howell-Jolly body-like inclusions have been previously associated with patients who are human immunodeficiency virus (HIV) infected, taking antiviral medications, and immunosuppressed. These inclusions...

• Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia

  Author:Gillian M. KeatingFrom:Drugs (Vol. 69, Issue 17) Peer-Reviewed

  Dec. 3, 200910,521 words Report Azacitidine (Vidaza[R]) is a pyrimidine nucleoside analogue of cytidine. Sub cutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell...

• Discovering Transcription and Splicing Networks in Myelodysplastic Syndromes

  Authors:Hongyan Wang, Jianguo Wen, Chung-che Chang, and Xiaobo ZhouFrom:PLoS ONE (Vol. 8, Issue 11) Peer-Reviewed

  Nov. 14, 20137,379 words Article 1400LMore and more transcription factors and their motifs have been reported and linked to specific gene expression levels. However, focusing only on transcription is not sufficient for mechanism research. Most genes,...

• Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis

  Authors:Jie Jin, Chao Hu, Mengxia Yu, Feifei Chen, Li Ye, Xiufeng Yin, et al.From:PLoS ONE (Vol. 9, Issue 6) Peer-Reviewed

  June 17, 20145,427 words Article 1470LBackground Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in...

• Closing in on the pathogenesis of the 5q- syndrome

  Authors:Sean M Post and Alfonso QuintaA s-CardamaFrom:Expert Review of Anticancer Therapy (Vol. 10, Issue 5) Peer-Reviewed

  May 20102,737 words Report 1610LAuthor(s): Sean M Post [[dagger]â ] 2 , Alfonso Quintáás-Cardama 1 Keywords : 5q- syndrome; miRNA 145; miRNA 146; myelodysplastic syndrome; TRAF6 Myelodysplastic syndromes (MDS) are a group of clonal...

• Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders.

  Authors:Kristen E. Schratz, Valeriya Gaysinskaya, Zoe L. Cosner, Emily A. DeBoy, Zhimin Xiang, Laura Kasch-Semenza, et al.From:Journal of Clinical Investigation (Vol. 131, Issue 18) Peer-Reviewed

  Sept. 15, 20215,788 words Report 1430LBACKGROUND. Germline mutations in telomerase and other telomere maintenance genes manifest in the premature aging short telomere syndromes. Myelodysplastic syndromes and acute myeloid leukemia (MDS/AML) account for 75%...

• Five-day Dacogen regimen

  From:MPR Hematology and Oncology Edition (Vol. 3, Issue 2)

  Summer 201096 words Brief article 1490LA five-day dosing regimen for Dacogen (decitabine for injection, from Eisai) has been approved to treat myelodysplastic syndromes. This dosing regimen provides the option of outpatient administration of Dacogen at a...

• Incremental gains and a long road ahead in MDS

  Authors:David P. Steensma and Ayalew TefferiFrom:Oncology (Vol. 22, Issue 12) Peer-Reviewed

  Nov. 15, 20081,506 words Clinical report 1890LSince the topic of risk-stratified management of patients with myelodysplastic syndromes (MDS) was last reviewed in ONCOLOGY in 2007, [1] a few additional clinically relevant studies have emerged that can help inform...

• KIR3DL1 and HLA-Bw4 Interaction Showed a Favorable Role in Patients with Myelodysplastic Syndromes in Chinese Southern Han.

  Authors:Jian Xin Zhen, Si Qi Cai, Yuan Tao Chen, Zhi Chao Yang, Jia Cai Zhuo, and Zhi Hui DengFrom:BioMed Research InternationalPeer-Reviewed

  May 31, 20203,102 words Article 1500LBackground. The association studies of killer cell immunoglobulin-like receptors (KIRs) with the occurrence of myelodysplastic syndromes (MDS) are limited worldwide; this study investigated the genetic risk/protective...

• p53 protein overexpression in bone marrow biopsies of patients with Shwachman-Diamond syndrome has a prevalence similar to that of patients with refractory anemia

  Authors:M. Tarek Elghetany and Blanche P. AlterFrom:Archives of Pathology & Laboratory Medicine (Vol. 126, Issue 4) Peer-Reviewed

  Apr. 20022,739 words Article Context.--Shwachman-Diamond syndrome (SDS) is a rare inherited disorder characterized by pancreatic insufficiency, neutropenia, and in some patients, metaphyseal dysostosis. Patients with SDS are at a high risk for...

• Management of myelodysplastic syndromes: Expert consensus opinion from the Saudi MDS Working Group

  Authors:Ahmed Alaskar, Abdul Al Momen, Ahmad Al-Saeed, Ahmed Al Sagheir, Amr Hanbali, Ayman Al-Hejazi, et al.From:Journal of Applied Hematology (Vol. 5, Issue 4) Peer-Reviewed

  October-December 20145,707 words Clinical report 1890LByline: Ahmed. Alaskar, Abdul. Al Momen, Ahmad. Al-Saeed, Ahmed. Al Sagheir, Amr. Hanbali, Ayman. Al-Hejazi, Hani. Al-Hashmi, Khalid. Al-Anazi, Mohsen. Al Zahrani, Saud. Harbesh, Zayed. Al-Zahrani Myelodysplastic...

• Lenalidomide: acute liver failure in an elderly patient with viral liver infection: case report

  From:Reactions Weekly (Issue 1292)

  Mar. 13, 2010372 words Brief article, Case ... [S] A 93-year-old man with viral liver infection developed acute liver failure during treatment with lenalidomide for low-risk myelodysplastic syndrome (MDS). The man had been found to be positive for hepatitis B...

• Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes

  Authors:Gerald B. Wertheim and Adam BaggFrom:Expert Review of Molecular Diagnostics (Vol. 11, Issue 4) Peer-Reviewed

  May 20114,534 words Report 1560LAuthor(s): Gerald B Wertheim 1 , Adam Bagg [[dagger]â ] 2 Keywords : acute myeloid leukemia; donor chimerism; hematopoietic stem cell transplant; high-grade myelodysplastic syndrome; minimal residual disease;...

• Various 'dendritic cell antigens'a[euro][TM] are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes

  Authors:Julia Dreyssig, Andreas Kremser, Anja Liepert, Christine Grabrucker, Markus Freudenreich, Christoph Schmid, et al.From:Immunotherapy (Vol. 3, Issue 9) Peer-Reviewed

  Sept. 20117,905 words Report 1470LAuthor(s): Julia Dreyssig 1 , Andreas Kremser 1 , Anja Liepert 1 , Christine Grabrucker 1 , Markus Freudenreich 1 , Christoph Schmid 2 , Tanja Kroell 1 , Nina Scholl 1 , Johanna Tischer 1 , Stephany Kufner 1 , Helmut...

• Hydroxychloroquine: secondary myelodysplastic syndrome

  From:Clin Alert (Vol. 45, Issue 13)

  July 15, 2007404 words Clinical report 1430LA retrospective chart analysis of 217 patients receiving hydroxychloroquine for rheumatological conditions was conducted to evaluate the occurrence of primary myelodysplastic syndromes (MDS). None of the patients had a...

• Myelodysplastic syndromes

  Authors:Donald C. Doll and Alan F. ListFrom:The Western Journal of Medicine (Vol. 151, Issue 2) Peer-Reviewed

  Aug. 19896,241 words Article Myelodysplastic syndromes include a number of disorders of the bone marrow cells responsible for the production of blood cells (hematopoiesis). The condition usually affects patients who are over 60 years of age and have...

• Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

  Authors:Stefan Stein, Marion G. Ott, Stephan Schultze-Strasser, Anna Jauch, Barbara Burwinkel, Andrea Kinner, et al.From:Nature Medicine (Vol. 16, Issue 2) Peer-Reviewed

  Feb. 20105,726 words Report 1590LGene-modified autologous hematopoietic stem cells (HSC) can provide ample clinical benefits to subjects suffering from X-linked chronic granulomatous disease (X-CGD), a rare inherited immunodeficiency characterized by...

• Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

  Authors:Daniel T. Starczynowski, Florian Kuchenbauer, Bob Argiropoulos, Sandy Sung, Ryan Morin, Andrew Muranyi, et al.From:Nature Medicine (Vol. 16, Issue 1) Peer-Reviewed

  Jan. 20107,107 words Clinical report 1570L5q- syndrome is a subtype of myelodysplastic syndrome characterized by severe anemia and variable neutropenia but normal or high platelet counts with dysplastic megakaryocytes. We examined expression of microRNAs...